Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells

Luke H. Hoeppner, Ying Wang, Anil Sharma, Naureen Javeed, Virginia P. Van Keulen, Enfeng Wang, Ping Yang, Anja Roden, Tobias D Peikert, Julian R Molina, Debabrata Mukhopadhyay

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We sought to determine whether Dopamine D2 Receptor (D2R) agonists inhibit lung tumor progression and identify subpopulations of lung cancer patients that benefit most from D2R agonist therapy. We demonstrate D2R agonists abrogate lung tumor progression in syngeneic (LLC1) and human xenograft (A549) orthotopic murine models through inhibition of tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor cells. Pathological examination of human lung cancer tissue revealed a positive correlation between endothelial D2R expression and tumor stage. Lung cancer patients with a smoking history exhibited greater levels of D2R in lung endothelium. Our results suggest D2R agonists may represent a promising individualized therapy for lung cancer patients with high levels of endothelial D2R expression and a smoking history.

Original languageEnglish (US)
Pages (from-to)270-281
Number of pages12
JournalMolecular Oncology
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Dopamine D2 Receptors
Dopamine Agonists
Lung Neoplasms
Neoplasms
Lung
Smoking
History
Heterografts
Endothelium
Myeloid-Derived Suppressor Cells
Therapeutics

Keywords

  • Angiogenesis
  • Cabergoline
  • Dopamine
  • Dopamine D2 receptor agonists
  • Lung cancer
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. / Hoeppner, Luke H.; Wang, Ying; Sharma, Anil; Javeed, Naureen; Van Keulen, Virginia P.; Wang, Enfeng; Yang, Ping; Roden, Anja; Peikert, Tobias D; Molina, Julian R; Mukhopadhyay, Debabrata.

In: Molecular Oncology, Vol. 9, No. 1, 01.01.2015, p. 270-281.

Research output: Contribution to journalArticle

@article{481d8ccf8d7346b89b55ee8f13b8c84e,
title = "Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells",
abstract = "We sought to determine whether Dopamine D2 Receptor (D2R) agonists inhibit lung tumor progression and identify subpopulations of lung cancer patients that benefit most from D2R agonist therapy. We demonstrate D2R agonists abrogate lung tumor progression in syngeneic (LLC1) and human xenograft (A549) orthotopic murine models through inhibition of tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor cells. Pathological examination of human lung cancer tissue revealed a positive correlation between endothelial D2R expression and tumor stage. Lung cancer patients with a smoking history exhibited greater levels of D2R in lung endothelium. Our results suggest D2R agonists may represent a promising individualized therapy for lung cancer patients with high levels of endothelial D2R expression and a smoking history.",
keywords = "Angiogenesis, Cabergoline, Dopamine, Dopamine D2 receptor agonists, Lung cancer, VEGF",
author = "Hoeppner, {Luke H.} and Ying Wang and Anil Sharma and Naureen Javeed and {Van Keulen}, {Virginia P.} and Enfeng Wang and Ping Yang and Anja Roden and Peikert, {Tobias D} and Molina, {Julian R} and Debabrata Mukhopadhyay",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.molonc.2014.08.008",
language = "English (US)",
volume = "9",
pages = "270--281",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells

AU - Hoeppner, Luke H.

AU - Wang, Ying

AU - Sharma, Anil

AU - Javeed, Naureen

AU - Van Keulen, Virginia P.

AU - Wang, Enfeng

AU - Yang, Ping

AU - Roden, Anja

AU - Peikert, Tobias D

AU - Molina, Julian R

AU - Mukhopadhyay, Debabrata

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We sought to determine whether Dopamine D2 Receptor (D2R) agonists inhibit lung tumor progression and identify subpopulations of lung cancer patients that benefit most from D2R agonist therapy. We demonstrate D2R agonists abrogate lung tumor progression in syngeneic (LLC1) and human xenograft (A549) orthotopic murine models through inhibition of tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor cells. Pathological examination of human lung cancer tissue revealed a positive correlation between endothelial D2R expression and tumor stage. Lung cancer patients with a smoking history exhibited greater levels of D2R in lung endothelium. Our results suggest D2R agonists may represent a promising individualized therapy for lung cancer patients with high levels of endothelial D2R expression and a smoking history.

AB - We sought to determine whether Dopamine D2 Receptor (D2R) agonists inhibit lung tumor progression and identify subpopulations of lung cancer patients that benefit most from D2R agonist therapy. We demonstrate D2R agonists abrogate lung tumor progression in syngeneic (LLC1) and human xenograft (A549) orthotopic murine models through inhibition of tumor angiogenesis and reduction of tumor infiltrating myeloid derived suppressor cells. Pathological examination of human lung cancer tissue revealed a positive correlation between endothelial D2R expression and tumor stage. Lung cancer patients with a smoking history exhibited greater levels of D2R in lung endothelium. Our results suggest D2R agonists may represent a promising individualized therapy for lung cancer patients with high levels of endothelial D2R expression and a smoking history.

KW - Angiogenesis

KW - Cabergoline

KW - Dopamine

KW - Dopamine D2 receptor agonists

KW - Lung cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84920398036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920398036&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.08.008

DO - 10.1016/j.molonc.2014.08.008

M3 - Article

VL - 9

SP - 270

EP - 281

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 1

ER -